Publications by authors named "D Priantono"
: Indonesia, as a developing country, has limited data on the factors associated with 30-day mortality in COVID-19 patients in Indonesia. As a matter of fact, study analyzing factors associated with 30-day mortality of COVID-19 infection in Indonesia has never been conducted. This study aims to fill this gap in the literature by conducting a large-scale analysis of factors associated with 30-day mortality in COVID-19 patients in Indonesia.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic breast cancer is linked to high levels of morbidity and mortality, with a focus on how insulin resistance might impact its occurrence.
- The study analyzed data from 150 breast cancer patients to examine the relationship between insulin resistance, measured by HOMA-IR and TyG Index, and the incidence of metastatic cancer.
- Results indicated no significant correlation between insulin resistance metrics and the incidence of metastatic breast cancer, suggesting that insulin resistance may not be a contributing factor.
Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of peripheral T-cell lymphoma. Patients usually present with splenomegaly and pancytopenia but without lymphadenopathy. Immunohistochemistry (IHC) staining of bone marrow biopsy shows intra-sinusoidal infiltration of CD3 and CD56 T-lymphocytes.
View Article and Find Full Text PDFBackground: Cancer patients have an increased risk of a severe COVID-19 infection with higher mortality rate. This study aimed to analyze the levels of anti-SARS-CoV-2 S-RBD IgG and NAB among cancer patients who were vaccinated with COVID-19 vaccines, either with BNT162b2, mRNA-1273, AZD1222/ChAdOx1nCoV-19, or Coronavac/BBIBP-CorV vaccines.
Method: A cross-sectional study was conducted among subjects with either solid or hematological cancers who had received two doses of either mRNA or non-mRNA vaccines within 6 months.
Article Synopsis
- This study investigated the effectiveness of Covid Convalescent Plasma (CCP) in hospitalized patients with moderate COVID-19, as its efficacy in severe cases was previously unproven.
- Conducted as a randomized controlled trial in Jakarta, Indonesia, from November 2020 to August 2021, the main goal was to measure mortality rates at 14 days, with secondary outcomes including longer-term mortality and discharge times.
- Results showed no significant reduction in 14-day mortality for CCP versus standard treatment, but the CCP group did have lower mortality rates at 28 days and over the full follow-up period, though these differences weren’t statistically significant.